• Explore /
  • Poster
  • / Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.

Phase II trial of adjuvant de-escalated radiation + adjuvant nivolumab for intermediate-high risk P16+ oropharynx cancer.

Abstract Poster

Authors

null

Heath Devin Skinner

UPMC Hillman Cancer Center, Department of Radiation Oncology, Pittsburgh, PA

Heath Devin Skinner , Dan Paul Zandberg , Adam Raben , Shaum Sridharan , Mark Kubik , Jose Zevallos , Seungwon Kim , Umamaheswar Duvvuri , James Ohr , William E. Gooding , Robert L. Ferris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03715946

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6014)

DOI

10.1200/JCO.2023.41.16_suppl.6014

Abstract #

6014

Poster Bd #

6

Abstract Disclosures

Similar Posters

First Author: Rohit K. Jain

First Author: Marlen Haderlein

First Author: Priyanka Sharma

First Author: Haitham Mirghani